Phase 1/2 Study of HQK-1001 in Patients With Beta Thalassemia

NCT00790127 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

21

Enrollment

INDUSTRY

Sponsor class

Conditions

Beta Thalassemia

Interventions

DRUG: HQK-1001
DRUG: Placebo

Sponsor

HemaQuest Pharmaceuticals Inc.